It has been suggested that the relative benefit of IDO1 inhibition may be greater in immune-cold tumours that constitutively express IDO1 (94), as it could enable increased lymphocyte infiltration and in turn amplify the utility of PD-1 or PD-L1 inhibition. Here, CD274 is linked to neoplasm.